Analyst Price Targets — MAZE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 14, 2026 11:12 am | — | Truist Financial | $64.00 | $27.42 | TheFly | Maze Therapeutics price target lowered to $64 from $68 at Truist |
| March 17, 2026 8:06 pm | Danielle Brill | Truist Financial | $68.00 | $50.39 | StreetInsider | Truist Securities Starts Maze Therapeutics (MAZE) at Buy |
| March 10, 2026 8:41 am | — | Mizuho Securities | $97.00 | $51.06 | TheFly | Maze Therapeutics initiated with an Outperform at Mizuho |
| January 19, 2026 5:12 pm | — | BTIG | $46.00 | $40.77 | TheFly | Maze Therapeutics price target raised to $46 from $37 at BTIG |
| December 19, 2025 1:07 pm | Debjit Chattopadhyay | Guggenheim | $46.00 | $41.92 | TheFly | Maze Therapeutics price target raised to $46 from $34 at Guggenheim |
| December 4, 2025 10:32 am | — | Wells Fargo | $55.00 | $41.49 | TheFly | Maze Therapeutics initiated with an Overweight at Wells Fargo |
| December 3, 2025 2:06 pm | — | H.C. Wainwright | $60.00 | $38.75 | TheFly | Maze Therapeutics price target raised to $60 from $50 at H.C. Wainwright |
| November 13, 2025 9:08 pm | — | Raymond James | $48.00 | $31.84 | TheFly | Maze Therapeutics initiated with a Strong Buy at Raymond James |
| September 15, 2025 10:42 am | Debjit Chattopadhyay | Guggenheim | $34.00 | $23.25 | TheFly | Maze Therapeutics price target raised to $34 from $19 at Guggenheim |
| September 2, 2025 10:38 am | — | BTIG | $30.00 | $15.32 | TheFly | Maze Therapeutics initiated with a Buy at BTIG |
Latest News for MAZE
Chief Medical Officer Harold Bernstein sold 15,000 company shares for a transaction value of ~$442,000 at around $29.46 per share on April 1, 2026. This disposition represented 100% of Harold Bernstein's direct Common Stock holdings, reducing his direct ownership of Common Stock to zero.
I am initiating coverage on Maze Therapeutics (MAZE) with a "Buy" rating following positive phase 2 HORIZON data for MZE829 in APOL1-mediated kidney disease. MZE829 achieved a 35.6% mean reduction in proteinuria, exceeding the ≥30% uACR threshold required for clinical relevance and potential regulatory advancement. Despite a 37% stock drop post-data, I view the market reaction as overblown given the program's…
The heavy selling pressure might have exhausted for Maze Therapeutics, Inc. (MAZE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Maze Therapeutics, Inc. (NASDAQ: MAZE). The investigation focuses on Maze's executive officers and whether investor losses may be recovered under federal securities laws.
An executive at Maze Therapeutics reported selling 15,000 shares on March 20, 2026, yielding a transaction value of $736,000 at around $49.10 per share. The activity was executed directly, involved derivative mechanics (option exercise), and did not affect any indirect holdings.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MAZE.
U.S. House Trading
No House trades found for MAZE.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.